Biological and Biochemical Product Manufacturing in China: Market Size, Businesses & Forecast 2026

The biological and biochemical product manufacturing industry in China focuses on the application of advanced biotechnology to produce vaccines, blood products, gene-engineered drugs, and diagnostic reagents. According to the National Bureau of Statistics (NBS), the total operating revenue of China's pharmaceutical firms above a designated size increased by 1.16% year-on-year in 2024 (National Bureau of Statistics). However, the sector faces pricing adjustments, evidenced by a net profit decline of 2.16% year-on-year in 2024 due to expanded state volume-based procurement initiatives (National Bureau of Statistics). The latest available data from 2024 and 2025 shows the industry shifting towa

Industry snapshot

Key public data points

Get in touch and our analysts will be happy to help with custom market sizing, deeper segmentation, supplier detail or a bespoke study built for you.

What does the Biological and Biochemical Product Manufacturing in China industry cover?

This industry encompasses enterprises utilizing modern biotechnology to perform industrial-scale processing of biological and biochemical substances. The sector's operational focus spans the extraction, modification, and synthetic generation of organic materials for medical and therapeutic uses. Its core outputs include therapeutic monoclonal antibodies, recombinant proteins, vaccines, nucleic acid components, and diagnostic materials.

• •Covers the manufacturing of biochemical drugs derived from animal, plant, and microbial origins.
• •Includes advanced genetic engineering fields such as gene therapy vectors and recombinant human insulin.
• •Excludes conventional synthetic chemical medicines and raw active pharmaceutical ingredients (APIs) classified under chemical synthesis sectors.

Who operates in the industry and how is it structured?

The domestic market features a blend of large-scale state-holding enterprises, domestic private innovators, and localized multinational operations. Firms operate within a highly capitalized environment due to the capital-intensive nature of bioreactor infrastructure and cell-line development. Industrial clustering is pronounced, with operations heavily concentrated in specialized bio-parks across coastal and tier-one economic zones.

• •State-backed groups play a foundational role in national vaccine programs and critical blood-product supply lines.
• •A substantial share of national output is driven by industrial manufacturing facilities with annual revenues exceeding 20 million yuan.
• •Contract Development and Manufacturing Organizations (CDMOs) form a core sub-segment, providing manufacturing infrastructure for domestic and global biotechs.

What drives demand in the industry?

The domestic market is propelled by profound demographic changes and structural healthcare reforms. An expanding elderly population increases the clinical prevalence of chronic oncology, metabolic, and cardiovascular conditions suited for biological therapies. Concurrently, government-led expansion of public medical insurance creates baseline demand for large-volume bio-therapeutics.

• •Demographic pressures are intensifying, with over 75% of China's elderly population living with at least one chronic medical condition.
• •Increased commercial insurance penetration and public safety-net expansions ensure sustained demand for therapeutic vaccines and biologics.
• •Clinical trials listed in public registries surpassed 7,100 initiatives in 2024, demonstrating strong upstream demand for clinical manufacturing services.

Who are the notable companies in the industry?

Competition within the industry is intense, characterized by domestic leaders moving away from basic generics toward complex biosimilars and novel biologics. Large players leverage automated facilities and strategic international joint ventures to offset domestic downward pricing pressures. Leading firms are expanding their specialized manufacturing capacities to meet strict international standards, enabling them to capture market share abroad.

• •WuXi Biologics (Cayman) Inc. serves as a prominent global contract manufacturer with major operational hubs located across China.
• •Shanghai Pharmaceuticals Holding Co., Ltd. maintains extensive manufacturing facilities alongside international commercial distribution partnerships.
• •Sinopharm Group Co., Ltd. commands a leading role in large-scale vaccine manufacturing and distribution networks nationwide.
• •Jiangsu Hengrui Pharmaceuticals Co., Ltd. has shifted significant capital into proprietary biological pipelines, including antibody-drug conjugates (ADCs).

What are the recent trends and outlook?

The manufacturing sector is entering a phase of mature optimization following an intensive period of capital investment and regulatory expansion. Accelerated regulatory pathways are favoring 'improved new drugs' that utilize optimized formulation processes or modified administration routes. Firms are prioritizing manufacturing efficiency, multi-product facility optimization, and automation to protect operating margins.

• •Biologics and biosimilars grew to account for approximately 32% of the overall Chinese pharmaceutical market structure by 2024.
• •More than 53% of improved new therapeutic formulations approved between 2020 and 2025 successfully utilized accelerated bioequivalence pathways.
• •Since the initiation of the 14th Five-Year Plan, Chinese regulatory bodies have formally cleared more than 113 innovative new drug applications.

How is the industry regulated?

Manufacturing protocols are rigorously monitored under the supervision of the National Medical Products Administration (NMPA). Stringent adherence to domestic Good Manufacturing Practice (GMP) guidelines is a mandatory legal prerequisite for industrial operation. Furthermore, the market is structurally influenced by state-driven centralized Volume-Based Procurement (VBP), which systematically rewards scaled, cost-efficient operators.

• •Firms face rigid pricing pressure inside public channels as the increasing scale of the VBP system compresses historical brand margins.
• •Manufacturing facilities must clear specialized dual audits to export products directly to North American or European Union markets.
• •Regulatory enforcement includes unannounced on-site audits focusing heavily on biological batch data integrity and cell-line traceability.

Government, statistical and trade sources used for this Claight analysis.

• National Bureau of Statistics of China 2025 Reports ·
• National Medical Products Administration (NMPA) Public Registries 2025 ·
• World Health Organization (WHO) International Clinical Trials Registry Platform 2024 Data Release